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A b s t r A c t
Extramedullary relapse constitutes an uncommon manifestation of multiple my-
eloma, but central nervous system involvement as the only manifestation of relapse 
appears even less common. A 50-year-old man with a history of multiple myeloma 
achieved complete remission after autologous hematopoietic stem cell transplanta-
tion. Fifteen months later, he presented with central nervous relapse with no signs of 
systemic disease.
A 50-year-old man with a history of IgA-lambda multiple myeloma (MM) achieved 
complete remission after high dose chemotherapy followed by autologous hematopoi-
etic stem cell transplantation. Fifteen months later, he presented with a hoarse voice, 
numbness and cauda equina syndrome. Complete blood count and a peripheral blood 
smear at this time showed normal hemoglobin (13.6 g/dL; normal range 13.5-17.5 g/dL), 
leukocyte count (8.6×109/L; normal range 4-11×109/L), and platelet count (169×109/L; 
normal range 150-350×109/L). There was no evidence of a monoclonal component in 
the blood and urine as measured by serum protein electrophoresis and immunofixa-
tion. Serum kappa free light chains were 9.74 mg/L (normal range 3.3-19.4 mg/L), 
lambda free light chains 5.07 mg/L (normal range 5.71-26.3 mg/L) and free kappa/
lambda ratio 1.92 (normal range 0.26-1.65). In addition, the serum calcium level (2.3 
mmol/L; normal range 2.3-2.74 mmol/L) and renal function (creatinine, 57.4 μmol/L; 
normal range 53-106 μmol/L) were normal. 
Microscopic analysis of the cerebrospinal fluid revealed infiltration by abnormal 
plasma cells (Fig. A); some cells contained mitotic features (thick arrow), others 
contained intranuclear Dutcher bodies (arrowhead) and some were binucleated (ar-
row). Immunophenotypic evaluation revealed the presence of plasma cells using the 
markers CD38 and CD138 (Fig. B), while lambda light chain clonality was confirmed 
(Fig. C). Spinal cord magnetic resonance imaging showed multiple epidural nodules. 
Osteolytic lesions were not detected.
●●●
Neurological manifestations frequently accompany MM, and these manifestations 
may occur in the setting of metabolic disorders, hyperviscosity syndrome, spinal cord 
or nerve root compression, amyloidosis or peripheral neuropathies due to chemo-
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therapy toxicity.1 On the contrary, central nervous system 
(CNS) involvement in MM is extremely rare. It may present 
with solitary or multiple intraparenchymal plasmacytomas 
due to extention of lesions of the skull and/or leptomeningeal 
disease with abnormal cerebrospinal fluid findings in advanced 
stages of the disease.2,3 Cases of isolated CNS relapse of MM 
after autologous hematopoietic stem cell transplantation are 
very few in the literature.1,4,5 Factors that reliably predict MM 
relapse in the CNS are uncertain.4 
In recent years, multiparametric flow cytometry has be-
come mandatory in the clinical management of hematological 
malignancies, both for diagnostic and monitoring purposes. 
Flow cytometry gives the ability to identify plasma cells among 
other hematopoietic cells, characterize aberrant plasma cell 
phenotypes and confirm clonal nature of plasma cells.6,7 Cen-
tral nervous system MM portends a poor survival prognosis 
and currently has limited treatment options. The efficacy of 
immunomodulatory drugs and proteasome inhibitors in such 
cases has to be demonstrated in future clinical trials.8,9
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